2026-03-12T08:09:21Z https://repository.lib.tottori-u.ac.jp/oai

oai:repository.lib.tottori-u.ac.jp:00007103 2023-11-22T01:45:34Z 1:9 2:12

Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus 小山, 哲史 コヤマ, サトシ Koyama, Satoshi 90403419 藤原, 和典 フジワラ, カズノリ Fujiwara, Kazunori 70403417 中村, 陽祐 ナカムラ, ヨウスケ Nakamura, Yosuke 80403418 福原, 隆宏 フクハラ, タカヒロ Fukuhara, Takahiro 40197273 竹内, 裕美 タケウチ, ヒロミ Takeuchi, Hiromi Morisaki, Tsuyoshi Fujii, Taihei © 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved. Basaloid squamous cell carcinoma Cetuximab Head and neck Metastasis Chemotherapy Basaloid squamous cell carcinoma Cetuximab Head and neck Metastasis Chemotherapy Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and distant metastases. To date few articles regarding chemotherapy for metastatic disease have been reported, thus feasible chemotherapy is not well established. Cetuximab is a monoclonal antibody for epithelial growth factor receptor (EGFR), which has great efficacy for head and neck squamous cell carcinoma due to EGFR signaling pathway blockage. Because BSCC also highly expresses EGFR, cetuximab may be effective for BSCC. We report here a first case of recurrent BSCC in the ethmoid sinus with intracranial extension treated with cetuximab-based chemotherapy, which revealed great response in a 40-year-old man. Positron emission tomography (PET) revealed no lymph node or distant metastasis. The patient underwent chemoradiotherapy 66 Gy in 33 fractions with triweekly 100 mg/m2 cisplatin. However, 12 weeks after treatment completion PET revealed a residual tumor at the primary cancer site. Combination therapy with weekly paclitaxel and cetuximab was started, and complete response was observed 2 months from treatment initiation. The patient has maintained complete response for 32 months, and no tumor regrowth has been observed. Elsevier B.V. 2021-12 eng journal article AM https://repository.lib.tottori-u.ac.jp/records/7103 10.1016/j.anl.2020.07.002 Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. Auris Nasus Larynx. 48(6), 1189-1192. 2020-07-16. https://www.sciencedirect.com/science/article/pii/S0385814620301590 https://www.sciencedirect.com/science/article/pii/S0385814620301590 03858146 Auris Nasus Larynx Auris Nasus Larynx 48 6 1189 1192 https://repository.lib.tottori-u.ac.jp/record/7103/files/anl48(6)_1189.pdf application/pdf 482.8 kB 2023-01-01